Introduction:
Due to prolonged inflammation in the colon, individuals with inflammatory bowel disease (IBD) face an elevated risk of developing colorectal cancer (CRC). Factors contributing to this risk include the duration and severity of the disease, family history of CRC, presence of primary sclerosing cholangitis, and active inflammation observed during endoscopy and histological examinations. It is believed that carcinogenesis in IBD follows a sequential progression, starting with chronic inflammation, leading to dysplasia (first low-grade, then high-grade), and ultimately culminating in adenocarcinoma.
Some individuals undergoing surveillance may develop cancer without prior histological signs of dysplasia, while others may advance directly from low-grade dysplasia (LGD) to carcinoma. Surgical intervention is typically recommended for high-grade dysplasia (HGD), especially since concurrent adenocarcinoma is often found in a significant proportion of resected colons. However, the management of LGD remains uncertain due to the unclear natural progression of this condition.
What Is Inflammatory Bowel Disease (IBD)?
Inflammatory bowel disease (IBD) manifests as recurrent inflammation of the gastrointestinal tract, triggered by an abnormal immune response to gut microflora. It comprises two distinct types of idiopathic intestinal disorders distinguished by their location and depth of involvement in the bowel wall.
Ulcerative colitis (UC) primarily involves diffuse inflammation of the colonic mucosa. It commonly begins in the rectum (proctitis) but can extend to the sigmoid (proctosigmoiditis), beyond the sigmoid (distal ulcerative colitis), or affect the entire colon up to the cecum (pancolitis). On the other hand, Crohn's disease (CD) results in transmural ulceration affecting any part of the gastrointestinal tract (GI), with the terminal ileum and colon being the most frequently affected sites. Both diseases are categorized based on their extent (mild, moderate, or severe) and location, with CD further classified by phenotype into inflammatory, stricturing, or penetrating forms.
Aside from GI involvement, both Crohn's disease and ulcerative colitis exhibit numerous extraintestinal manifestations. While most patients can be clinically differentiated, approximately 10% present with similar features that the initial distinction between the two disorders proves challenging.
Genetic predisposition contributes to both conditions, which are chronic and incurable, imposing significant morbidity. Furthermore, both diseases elevate the risk of colorectal cancer.
Is Dysplasia Common in Irritable Bowel Syndrome?
Colorectal dysplasia and cancer pose significant concerns for individuals with inflammatory bowel disease (IBD) affecting the colon. While there appears to be a decreasing incidence of colorectal neoplasia (CRN) in the IBD population, the risk of colorectal cancer (CRC) remains approximately twice as high as that in non-IBD populations, according to both referral-based and population-based studies. This elevated risk is influenced by disease-related factors such as the cumulative inflammatory burden and extent of disease, as well as patient-level risk factors like concomitant primary sclerosing cholangitis (PSC) and a family history of CRC.
In IBD, CRC typically develops through a progression starting with inflammation, followed by varying degrees of dysplasia, before malignant transformation to cancer. Despite advancements in understanding IBD pathogenesis and management, there's still no definitive way to prevent or predict neoplastic complications. Efforts to identify noninvasive biomarkers for risk stratification and better prediction of those who would benefit most from surveillance and aggressive management have not yet yielded reliable clinical tools. Instead, risk stratification relies on clinical factors such as PSC, prior dysplasia, and endoscopic and histologic disease activity.
While no chemopreventive agents have proven effective, CRC prevention primarily involves risk reduction strategies such as enrollment in a surveillance program, smoking cessation, and adherence to medical therapy for deep remission. Although routine surveillance colonoscopy has limitations, costs, and patient inconvenience, it remains the most effective means of diagnosing, preventing, and occasionally resecting colorectal neoplasia.
What Are the Risk Factors of Dysplasia in Irritable Bowel Syndrome?
-
While certain risk factors for CRN in inflammatory bowel disease (IBD) are well-established, such as disease duration, extent, and inflammation severity, others, like the male sex, show some discrepancies in the literature.
-
Patient-specific factors like primary sclerosing cholangitis (PSC), prior CRN history, family history of colorectal cancer (CRC), and possibly younger age of disease onset also play a role in decision-making.
-
Disease extent and duration, along with concomitant PSC, pose the highest and most consistent risks for developing dysplasia, or CRC, in IBD.
-
Pancolitis and PSC significantly elevate the risk, with certain factors, like a family history of CRC at a young age, also playing a significant role.
-
As indicated by endoscopic or histologic findings, disease activity further influences the risk of progression to CRN.
-
Structural changes resulting from chronic inflammation, such as strictures and pseudopolyps, are recognized risk factors for CRC.
-
Strictures with specific characteristics, such as right-sided location, symptomatic presentation, or changes over time, warrant closer surveillance and possibly resection.
How to Manage Dysplasia Caused by Irritable Bowel Syndrome?
Management of visible dysplasia in inflammatory bowel disease (IBD) involves a multifaceted approach, including therapeutic resection (endoscopic or surgical), ongoing medical management for disease control, and close surveillance. Criteria for endoscopic resectability are not strictly defined but depend on factors like lesion characteristics and patient preference. Endoscopic resection aims for en bloc removal with negative margins, but challenges arise in IBD due to inflammation-related fibrosis.
Patient selection for endoscopic versus surgical resection involves thoroughly discussing risks and continued surveillance needs. Polypoid lesions are typically amenable to en-bloc resection, while non-polypoid lesions require careful consideration and may necessitate surgical referral due to the higher risks of incomplete resection and recurrence. Surveillance intervals following resection depend on lesion characteristics and histologic findings, with close monitoring recommended for optimal outcomes.
Management of endoscopically "invisible" dysplasia involves thorough assessment and surveillance. Confirmation by an expert pathologist is essential if dysplasia is suspected from random biopsies. Subsequent colonoscopy with enhanced detection techniques should be performed to identify any visible lesions. If no lesions are found, additional random biopsies should be taken. If dysplasia is confirmed again, individual patients and disease-related risk factors for colorectal cancer (CRC) should be considered in deciding further management.
Surveillance intervals are shortened if low-grade dysplasia (LGD) is detected, and colectomy should be discussed with the patient. High-grade dysplasia (HGD) warrants confirmation by an expert pathologist, followed by consideration of endoscopic resection or colectomy. In ulcerative colitis (UC), dysplasia is considered a field defect justifying total colectomy, while the approach in segmentally affected Crohn's colitis is less clear. Total proctocolectomy is often recommended due to the high synchronous and metachronous neoplasia risks. However, the outcomes of segmental resection versus total colectomy in Crohn's colitis with HGD remain under investigation.
Conclusion:
Dysplasia is crucial in defining inflammatory bowel disease (IBD)-related dysplasia as an epithelial malformation that is neoplastic yet noninvasive. Given its clinical significance, precise diagnosis is vital, though microscopic diagnosis remains challenging. Differential diagnosis between polypoid IBD-related dysplasia and sporadic adenomas, as well as therapy-related 'pseudodysplasia', is essential. Seeking a second opinion is often warranted. Genetic testing aids in confirming diagnosis by identifying molecular changes associated with carcinogenesis, although their timing and significance vary. Positive findings indicate increased cancer risk, necessitating clinical action, usually surgery, due to dysplasia's role as a potential precursor or marker of malignancy. However, sporadic adenomas may be locally removed.
